Moreover, and uniquely in pancreatic cancer studies, research indicated that lower IL-6 might associate with a better disease outcome (39), where IL-6 clearly acts as a pro-inflammatory biomarker for this cancer type. Here, IL6 is linked to familial pancreatic carcinoma.